在第三阶段试验中,PartIQoL、质子波束疗法和IMRT对中低风险前列腺癌表现出同等的效力和类似安全性。 In a phase III trial, PARTIQoL, proton beam therapy and IMRT showed equal effectiveness and similar safety for low- and intermediate-risk prostate cancer.

第三阶段试验 " PartIQoL " 发现,质子波束疗法和强度调控辐射疗法对中低风险前列腺癌同样有效,在患者生活质量方面没有显著差异。 A phase III trial, PARTIQoL, found that proton beam therapy and intensity modulated radiation therapy (IMRT) are equally effective for low- and intermediate-risk prostate cancer, showing no significant differences in patient quality of life. 该研究涉及450名病人,并报告了类似的五年逐步无病存活率(IMRT为93.7%,质子疗法为93.4%)。 The study involved 450 patients and reported similar five-year progression-free survival rates (93.7% for IMRT and 93.4% for proton therapy). 这两种治疗都被认为是安全的,建议进一步研究病人分组可能是有益的。 Both treatments are deemed safe, suggesting further research on patient subgroups may be beneficial.